Targets › LYZ
2 programs from 2 companies in 4 trials: 3 Phase 3, 1 Phase 1; Oncology, Gastroenterology; next expected readout Dec 2026.
Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents. (UniProt, P61626)
Open in Phaseline: the race on LYZ, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Washington | Lactoferrin Combination of iron-binding glycoprotein and antimicrobial enzyme for enhanced intestinal | LTF, LYZ | Phase 3 | Diarrhea | Dec 2026 |
| City of Hope Medical Center | Human Lysozyme Goat Milk Recombinant human lysozyme in goat milk - antimicrobial enzyme that promotes beneficial gu | LYZ | Phase 1 | Allogeneic Hematopoietic Stem Cell Transplant Recipient | – |
Diarrhea (3) Allogeneic Hematopoietic Stem Cell Transplant Recipient (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.